In 2015, Chris Riopelle’s best friend called him with a question about his kidneys. The subject wasn’t as weird as it might sound, because Riopelle was an executive at Denver-based DaVita, the nation’s largest dialysis company, at the time. The friend’s doctor had recommended he see a nephrologist about some lab numbers, and Riopelle asked to look at the test results. Within hours, on Riopelle’s advice, his BFF was headed to the emergency room in a race against kidney failure. The friend eventually received a transplant, but the experience reinforced to Riopelle the warped manner in which health care handles kidney disease: Mostly eschewing early detection, the industry focuses on end-stage care (i.e., dialysis). “Of all people, I’m the one who said, ‘Hey, buddy, your kidneys aren’t working,’” Riopelle says.…
